“…Assessment of gross wound size, planimetry, presence of the scab, re-epithelialization by histology, tensile/breaking strength, tensile stiffness, fibrosis, cellular infiltrate, microbial composition, inflammation, granulation tissue formation, and transcutaneous water loss are among the methods used to evaluate wound healing. Even if one chooses to ignore the obvious structural differences between human and mouse skin ( Figure 1) and does not take into account additional biological variables (age, sex, microbiome, location), it becomes clear that reproducibility and extrapolation of data, as well as comparison among published studies, is very challenging, especially when details of experimental design are missing (Ansell et al, 2018). As an example, recombinant human platelet-derived growth factor-BB, which has received U.S. Food and Drug Administration approval for treatment of diabetic foot ulcers, shows variable efficacy in preclinical murine models, ranging from improved wound closure of 1.5-cm excisional diabetic mouse wounds (Greenhalgh et al, 1990), to significant increase of granulation tissue without improvement in the time to wound closure (and only in the 1.5-cm but not in 0.6-to 1.0-cmediameter excisional wounds) (Chan et al, 2006), to no effect on reepithelialization in a murine splinted diabetic wound model (Park et al, 2014).…”